BEIJING, March 11 (Reuters) - Eli Lilly ( LLY ) plans to

invest $3 billion over the next decade to expand supply chain

capacity in China and build production capacity for type-2

diabetes and obesity treatment orforglipron, the pharmaceuticals

giant said in a statement.

The company submitted marketing application for orforglipron

to China's drug regulator at the end of 2025, it said.

It also aims to establish a localised manufacturing and

supply system for oral solid dosage forms, the statement

showed.

(Reporting by Beijing Newsroom. Editing by Mark Potter

)